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Identification of Small Molecule Inhibitors that
Distinguish between Non-Transferrin Bound Iron
Uptake and Transferrin-Mediated Iron Transport
One very important area of nutrient transport lacking
pharmacological reagents for advanced study concerns
the uptake of iron. A commonly recognized pathway for
iron uptake by mammalian cells is through receptor-
mediated endocytosis of transferrin (Tf). Once internal-
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Boston, Massachusetts 02115 ized with its receptor, diferric Tf is delivered to endo-
somes wherein iron is released due to the low pH of
this compartment [17]. Mechanistically, transport of iron
released from Tf across endosomal membranes isSummary
thought to involve the reduction of Fe(III) to Fe(II) [18–20],
but the actual iron-translocating machinery has yet toChemical genetics is an emerging field that takes ad-
be rigorously defined. A strong candidate membranevantage of combinatorial chemical and small molecule
carrier has emerged called DMT1 [21]. Divalent Metallibraries to dissect complex biological processes. Here
Transporter 1 (DMT1, also known as DCT1 and Nramp2)we establish a fluorescence-based assay to screen for
is known to be involved in iron assimilation, since de-inhibitors of iron uptake by mammalian cells. Using
fects in its gene promote microcytic anemia in the mkthis approach, we screened the National Cancer Insti-
mouse, a genetic model with defective dietary iron ab-tute’s Diversity Set library for inhibitors of non-trans-
sorption [22]. The functional activity of DMT1 has beenferrin bound iron uptake. This screen identified 10
characterized using exogenous expression in Xenopusnovel small molecule inhibitors of iron transport with
oocytes [23]. In addition to its function in Fe(II) uptake,IC50 values that ranged from 5 to 30 M. Of these ten
a role for DMT1 in assimilation of iron from Tf was eluci-compounds, only two blocked uptake of iron mediated
dated by the discovery that its gene is also mutated inby transferrin. Thus, this study characterizes the first
the Belgrade rat [21]. Defects in Tf-mediated iron uptakesmall molecule inhibitors that distinguish between dif-
are well characterized for this animal model [24–26]. Tfferent pathways of iron transport.
is internalized by Belgrade rat reticulocytes, but its
cargo iron fails to be captured because of a loss of
Introduction transmembrane transport activity in the endosome [27,
28]. The observation that the pH-dependent DMT1
Classical genetics is based on determining phenotypic transporter localizes to acidic endosomal compart-
changes that result from mutation of genes and ordering ments further supports its role in this process [29, 30].
those identified genes into functional pathways. By anal- However, direct functional evidence to fully support this
ogy, the emerging field of chemical genetics takes ad- model is lacking, and how ferric iron is reduced after its
vantage of small molecule libraries to dissect complex release from Tf to make substrate available for DMT1
biological processes [1–3]. Past use of small molecule transport is still unknown. Furthermore, although Tf-
antagonists typically entailed “reverse genetics” to con- mediated iron uptake is a more widely recognized pro-
ditionally eliminate protein function and on that basis to cess, most cells also import nontransferrin bound iron
subsequently identify the target for inhibition. Studies (NTBI) presented as Fe(III) chelates [31–37]. The latter
of carrier-mediated transport to learn how nutrients, pathway plays a key role in the pathology of hemochro-
ions, and other factors enter or exit cells have often matosis since NTBI is found in serum from patients with
relied on such small molecule inhibitors: the cardiac this and other iron-overload disorders [38]. NTBI uptake
glycoside ouabain (an inhibitor of the Na-K ATPase), does not involve endocytic membrane traffic [32], and
the antibiotic cytochalasin B (an inhibitor of glucose apparent Km values for transport have been reported
transport), and the diuretic amiloride (an inhibitor of epi- between 0.5 and 20 M, falling in the range of serum
thelial Na channels) are just a few well-established ex- NTBI concentrations in patients with iron overload [38,
amples. These natural products were either fortuitously 39]. Characterization of this process indicates that it
discovered [4, 5] or actively sought as pharmacological also most likely involves ferrireduction of Fe(III) to Fe(II),
antagonists of transporter function [6] and were instru- but the mechanistic details of NTBI uptake are rather
mental in the analysis of transport mechanisms [4, 7, obscure [31]. It is possible that DMT1 functions in the
8], the identification of the molecules involved [9–13], import of NTBI from plasma, but this possibility has not
and in some instances, the elucidation of functionally been directly tested.
important domains [14–16]. There is a need, however, As a first step to determine mechanistic elements that
to develop “forward chemical genetics” to discover new may be unique to each of these iron transport pathways,
small molecules that interact with key elements in a we sought to identify small molecule inhibitors that se-
pathway of interest. Thus, the basis for forward chemical lectively inhibit NTBI uptake. To initiate the discovery
genetics is a phenotypic screen of small molecule librar- process, we have established a fluorescence-based
ies such that one can identify inhibitory (or stimulatory) assay useful for medium throughput screening of iron
effects by observing a change in cellular properties. transport inhibitors. Here we demonstrate the utility of
this chemical genetics approach by identifying ten novel
iron uptake inhibitors determined to block NTBI uptake.*Correspondence: wessling@hsph.harvard.edu
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Of these ten compounds, only two perturb Tf-mediated
iron assimilation, supporting the selectivity of the other
eight in blocking NTBI uptake. These reagents therefore
provide new chemical tools to help distinguish between
NTBI uptake and Tf-mediated iron transport and to en-
able further characterization of the determinants unique
to both processes at the molecular level.
Results
A Fluorescent Cell-Based Assay to Screen
for Small Molecule Inhibitors of Transport
To advance the study of iron transport through chemical
genetics, we established a fluorescence-based uptake
assay utilizing a 384-well format for medium-throughput
screening. Conceptually based on work by Cabantchik
and colleagues [40], the assay employs the metal-sensi-
tive fluorophore calcein to measure intracellular “labile”
or free iron. Iron taken up by cells transits the so-called
labile iron pool before deposition in ferritin (for storage)
or uptake by mitochondria (for metabolism). Calcein has
been used by several different groups to determine the
size of the labile iron pool under various conditions [41–
45]. Calcein fluorescence is quenched when iron or other
metals are bound [40]. Because calcein fails to bind
calcium or magnesium ions at physiological pH and the
intracellular concentration of other metals is relatively
low, a decrease in cell-associated calcein fluorescence
in the presence of an extracellular source of iron pro-
vides a relative measure of increased free intracellular
iron content due to iron uptake [40, 41]. For our studies,
we employed an acetomethyl ester of calcein (calcein-
AM). Upon entering cells, cellular esterases cleave this
compound, leaving the membrane impermeant fluoro-
phore resident inside cells with very little leakage as
long as cellular integrity is maintained. The loss of fluo-
rescence signal when iron is transported into cells re-
ports an increase in the cellular free iron pool, as as-Figure 1. Development of a Cell-Based Fluorescence Assay for Iron
sessed by the extent of fluorescence quenching. A keyUptake
advantage of this approach is that calcein fluorescence(A) Comparison of the ability of different iron sources to induce
changes in the intracellular labile iron pool as assayed by calcein also provides an indicator of cell viability such that the
fluorescence quenching. HeLa cells (1500) were seeded into each loss of fluorescent signal in the presence of a drug but
well of a 384-well plate, grown overnight, then washed 5 times with in the absence of iron reports the toxicity and/or fluores-
serum-free and phenol red-free DMEM and incubated with 0.25 M cence properties of that compound (see below).
calcein AM for 1 hr. After loading with the fluorophore, cells were
Preliminary analysis examining calcein quenching inwashed 10 times with HBSS and were subsequently incubated with
HeLa cells in response to iron uptake indicated that an150 M FAS (filled circles) or FAC (open circles), or 100 M Fe-NTA
(filled squares), 100 M Fe-NTA  Ascorbate (open squares), or appropriate determination could be made using 0.25
100 M Fe-Tf (triangles) in 50 l HBSS for times indicated. The M calcein to load these cells (signal 8-fold higher
fluorescence intensity (excitation 485 nm; emission 535 nm) of each than background). There was no substantial interference
well was measured before and after incubation with different iron from calcein-loading into nonviable cells (data not
sources to calculate the % change in fluorescence intensity as a
shown). Similarly, buffering, washing, and iron-loadingfunction of time.
conditions were each carefully examined. Studies using(B) Iron chelation by DFO blocks calcein fluorescence quenching
by Fe-NTA. HeLa cells were cultured and loaded with calcein as HBSS yielded optimal signal-to-noise ratios, and a mini-
described for (A) except that prior to addition of 100 M Fe-NTA, mum of 8 separate wash steps were required to elimi-
cells were pretreated with 0–500 M DFO in HBSS for 1 hr. The nate extracellular fluorophore (detected by quenching
fluorescence intensity was then measured before and after incuba- of extracellular calcein using Trypan blue). Figure 1A
tion with 100 M Fe(NTA)4 for 3 hr. The difference in fluorescence
demonstrates that under these carefully optimized con-intensity due to quenching was normalized to control (no treatment)
and is plotted as a function of inhibition by [DFO]. Shown are mean
values determined for triplicate samples.
(C) Time course of calcein fluorescence quenching. HeLa cells were
plated onto 384-well plates to determine the time course of fluores- different concentrations of Fe-NTA: 10 M (filled squares); 25 M
cence quenching exactly as described above except that incuba- (filled triangles); 50 M (open squares); 75 M (open triangles); and
tions were carried out in the absence (filled circles) or presence of 100 M (open circles).
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ditions, calcein-loaded HeLa cells display a time-depen- cence once again (Fd), add Fe-NTA (100 M final con-
centration), and incubate 2 hr at 37C; and step 7, mea-dent fluorescent quenching in the presence of various
sure fluorescence for a final reading (Ff).substrates for iron transport. Using this assay, uptake
During the screen, fluorescence measurements wereof iron from Tf, transport of NTBI (provided to cells as
compiled to calculate a viability and drug fluorescenceFe-NTA), and uptake ferrous iron (reduced in the pres-
index or (Fd  Fo)/Fo; this ratio for control cells (incu-ence of ascorbate) were measured. Maximal quenching
bated in the absence of any addition except vehiclewas observed by 2 hr for each of these transport sub-
DMSO) routinely fell within 5%–10%. Values for wellsstrates. Ferric ammonium sulfate (FAS) and ferric ammo-
treated with drug that were less than 10% (loss ofnium citrate (FAC), which are less bioavailable forms of
signal or apparent “quench”) indicated that the com-iron, did not quench the calcein signal as strongly.
pound was toxic such that cell viability was compro-To confirm that calcein fluorescence quenching was
mised or that the drug itself quenched calcein fluores-due to iron uptake, the iron-specific chelator desferriox-
cence. Values greater than 10% indicated that theamine (DFO) was introduced during transport incuba-
drug was fluorescent when excited at 485 nm. Thus, usetions along with Fe-NTA. As shown in Figure 1B, DFO
of the viability and drug fluorescence index eliminatedblocked the quenching effect observed in the presence
potential artifacts in the screening process. The viabilityof 100 M FeNTA, providing a “positive” control to
and drug fluorescence values were compared againstscreen for inhibitors of iron uptake since inhibition by
inhibition/activation values or (Fd  Ff)/Fd to eliminate100 M DFO was essentially complete. Finally, to con-
these “false positives.” The (Fd Ff)/Fd ratio of negativefirm that the change in fluorescence signal was dose
control cells (incubated with FeNTA but no DFO in theresponsive to extracellular iron concentration, a series
absence of any compound) was60% under our opti-of experiments that measured the time course of uptake
mized assay conditions. The values for positive controlwas performed using 10 to 100 M Fe-NTA (Figure 1C).
cells (incubated with Fe-NTA in the presence of DFO)Based on the results summarized in Figure 1, parame-
was 0%. Thus, any change between 0% and 60%ters for uptake studies were optimized to screen for
indicated that a compound inhibited uptake of Fe-NTAinhibition of iron uptake using Fe-NTA at 100 M with
by HeLa cells. In implementing this screening protocol,a 2 hr incubation at 37C to achieve maximal uptake
well-to-well and plate-to-plate variations were recog-and calcein fluorescence quenching.
nized that made it difficult to compare these calculated
values across the entire NCI Diversity Set (contained in
seven 384-well plates). It was necessary to develop aScreen of the NCI Diversity Set Library Identifies
mechanism to normalize across the library to directlyPotent Inhibitors of NTBI Uptake
compare potencies. For final analysis, the inhibition/Using the fluorescent cell-based iron uptake assay, we
activation ratio was normalized by setting the averagesurveyed the NCI Diversity Set library for inhibitors of
(Fd  Ff)/Fd ratio of 15 independent wells for negativeiron uptake because of its relatively small size (2000
control cells (calcein alone) to “0” as Fmin, and thecompounds) and molecular attributes (i.e., structurally
average (Fd  Ff)/Fd ratio of 15 independent wells forrepresents a finite set of pharmacophores). Further
positive control cells (calcein with FeNTA) to “1” as Fmax
information about the NCI Diversity Set is available
for each individual plate. The adjusted inhibition/activa-
at http://dtp.nci.nih.gov/branches/dscb/diversity_
tion values were then calculated as (Ff Fmin)/(Fmax
explanation.html. A pin-transfer robotic system was Fmin).
used to administer the compounds, permitting the trans- To validate candidates, the entire NCI Diversity Set
fer of fixed 10 nl aliquots from the small molecule library library was screened twice under identical conditions.
stocked at 10 mM compound in DMSO and provided Pooled data were carefully examined to eliminate non-
by Harvard Medical School Institute of Chemistry and specific effects (i.e., intrinsic fluorescence, cell toxicity)
Cell Biology (ICCB). Two independent pin-transfers were and to ensure reproducibility of strong inhibitory effects.
used for screening at a final nominal concentration of Ten compounds met these criteria with the structures
40 M. The rationale for this concentration of drug was shown in Table 1. These compiled data represent a “hit
that effective delivery of some compound could be as- rate” of 0.5%, supporting the selectivity of the assay
sured (2 rounds of transfer) while strong iron chelators for specific inhibitors. Samples of each of these com-
might be avoided in the selection process: e.g., 100 M pounds were subsequently obtained from Dr. Robert J.
Fe-NTA is effectively blocked by 100 M DFO but not Schultz, Drug & Chemistry Synthesis Branch at NCI;
40 M DFO (Figure 1B). We reasoned that similar iron drug reference numbers from the NCI Diversity Set are
chelators present in the library would be substoichio- given in Table 1. Each inhibitor was rescreened for the
metric and score only as “weak” inhibitors. Based on ability to inhibit Fe-NTA uptake using the calcein
the tansport assay conditions established above, the method, and dose response curves were constructed
screening protocol was adopted as follows: step 1, plate (Figure 2; derived IC50 values are shown in the table).
1500 HeLa cells/well on 384-well clear-bottom plates IC50 values ranged from 5 to 30 M, but several com-
and allow cells to attach overnight; step 2, wash cells pounds were found to be cytotoxic as indicated by the
twice, add 0.25M calcein-AM, briefly centrifuge plates, reversal of quenching and/or enhanced fluorescence
and incubate for 1 hr at 37C; step 3, wash cells 8 times (loss of cell viability) at higher concentrations (see atypi-
(twice in succession) with HBSS; step 4, measure initial cal “J” curves for 56M19, 56N16, 57H10, 56N08). While
fluorescence (Fo); step 5, robotically pin-transfer test this observation does not necessarily exclude the future
compounds or DFO controls, briefly centrifuge plates, utility of these inhibitors, it does caution about the nature
of these particular small molecules.and incubate for 30 min at 37C; step 6, measure fluores-
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Table 1. Inhibitors of NTBI Transport
Plate ID NCI # IC50 Structure Comments
57N19 11079 5 m Inhibits both NTBI and Tf-mediated
iron uptake
54C20 34908 20 m Structurally related to antifertility
and anoxia agents
54N20 75600 20 m GABA receptor ligand analog
56N08 48874 10 m Toxic 20 m; ACS Registry # 6640-40-0
56N16 48010 12 m Toxic 20 m
55L06 306711 5 m Inhibits both NTBI and Tf-mediated iron
uptake
55B05 331973 10 m Toxic? 30 m
56I18 27236 25 m Benzoic acid; chemical etching agent;
derivatives have fungal and
antibacteriocidal activity; metal
binding?
57H10 124808 30 m Toxic 50 m; commercially available
from Ambinter; metal ligand binding?;
antipsychotic hypnotic activities in
structurally related compounds
56M19 13831 15 m Toxic 40 m
Database searches of the CAS (Chemical Abstract conducted for information on the same or structurally
related compounds using the SciFinder Scholar searchServices) Registry, MEDLINE searches of the National
Library of Medicine, and searches of the American engine. Several compounds (54C20, 54N20, 56I18,
57H10) have been previously studied with commentsChemical Society (ACS) Registry of Compounds were
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Figure 2. Dose-Response Studies of Potent
NTBI Inhibitors
Inhibitory compounds listed in Table 1 were
obtained from Dr. Robert J. Schultz, Drug &
Chemistry Synthesis Branch at NCI and re-
tested for the ability to block uptake of iron
using the 384-well assay described in the text
with final concentrations between 0.5 nM and
100M. Average fluorescence values of tripli-
cate samples were used to determine (Ff 
Fmin)/(Fmax  Fmin) and plotted against in-
hibitor concentration.
listed in Table 1. Others (56N08) were found in the ACS tested, only two (57N19 and 55L06) had significant ef-
fects on TBI.Registry but with no further details, and for the rest
we were unable to find any information. None of the
compounds have been previously associated with cellu- Characterization of 57N19 and 55L06 Inhibition
of Tf-Mediated Iron Uptakelar iron transport.
The dose response for inhibition of Tf-mediated iron
uptake was examined for the two compounds that hadCharacterization of Transport Inhibitors
Distinguishes Mechanistic Differences significant inhibitory effects, 57N19 and 55L06 (Figure
4). IC50 values of 63 and 20 M, respectively, werebetween NTBI Uptake and Tf-Mediated
Iron Assimilation determined from this analysis. To test the reversibility
of inhibition, cells were first treated either with 55L06One of the immediate questions we addressed using
this set of inhibitors was whether they perturbed uptake or 57N19 for 2 hr or with both compounds for 1 hr,
followed by a 2 hr recovery period with vehicle (DMSO)of iron from Tf. Although some of the properties of NTBI
uptake and Tf-mediated iron assimilation appear similar added. Inhibition of Tf-mediated iron uptake and NTBI
transport were both reversed under the latter conditions(e.g, ferrireduction followed by membrane transloca-
tion), reaction conditions are quite different (e.g., uptake (Figure 5). These results confirmed that neither com-
pound is toxic to cells.across endosomal membrane at acidic pH versus trans-
port at the cell surface at neutral pH). Initially, the ten
inhibitors were screened at 50 M for effects on Tf Discussion
bound iron (TBI) uptake (Figure 3). Briefly, HeLa cells
were incubated with the small molecules for 4 hr at 37C This report establishes a cell-based screening method
that enables rapid identification of transport inhibitors(filled bars) or 4C (open bars) in the presence of 13 nM
55Fe-Tf. 55Fe uptake was quenched by chilling the cells with concurrent detection of cytotoxicity. Using calcein
fluorescence quenching as a measure of iron uptakeon ice and incubating with 40 M unlabeled Fe-Tf for 1
hr to any displace surface bound radiolabel [46, 47]. [40], we exploited use of this reagent as a vital stain for
cell viability [48, 49]. By establishing initial measure-Cell lysates were collected to measure cell-associated
radioactivity and protein content to calculate pmol ments for the viability and drug fluorescence index
[(Fd  Fo)/Fo], we were able to immediately identifyFe/mg protein as shown. Significant differences (p 
0.05) are indicated by an asterisk. Of the ten compounds those compounds exerting toxic effects, as well as those
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Figure 3. Effect of Inhibitors on Transferrin Bound Iron Uptake
HeLa cells were incubated with 50 M of the indicated compounds
for 4 hr at 37C (filled bars) or 4C (open bars) in the presence of 13
nM 55Fe-Tf. 55Fe uptake was quenched by chilling the cells on ice
and incubating with 40 M unlabeled Fe-Tf for 1 hr to displace
surface bound 55Fe-Tf; lysates were collected to measure cell-asso-
ciated radioactivity and protein content to calculate pmol Fe/mg
protein. Shown are the means SD with significant differences (p
0.05) indicated by an asterisk. Data were analyzed using ANOVA
and Fisher’s post hoc test.
with interfering intrinsic fluorescence or quenching proper-
Figure 4. 55L06 and 57N19 Inhibit Tf-Mediated Iron Uptake in aties. This approach streamlined our survey of normalized
Dose-Dependent Mannerinhibition/activation values [(Ff  Fmin)/(Fmax  Fmin)]
HeLa cells were incubated with 0.05–300 M 55L06 (top) and 57N19by eliminating potential small molecule inhibitors with
(bottom) in the presence of 13 nM unlabeled 55Fe-Tf for 4 hr at 37C.these nonspecific effects, ensured the reproducibility of
Cells were chilled on ice, incubated with 40 mM unlabeled Tf to
results, and led to immediate confirmation of the most displace any ligand bound iron associated with the cell surface, and
potent effectors. From our screen of the NCI Diversity then washed. Iron uptake was determined as described for Figure
3 and normalized to control (vehicle alone). Data shown are pooledSet library, 10 small molecule inhibitors that blocked
from three independent experiments measuring % inhibition foriron-induced calcein fluorescence quenching were se-
each compound.lected for further study based on these stringent criteria.
It should be noted that in our screen of this library many
“activators” of iron uptake were also concurrently identi-
fied. These compounds could promote iron absorption transport inhibition (25 M) is much lower than the con-
centration of Fe-NTA used in our study (100 M), andthrough a variety of different effects; for example, by
altering cell permeability to enhance iron uptake or by it is therefore unlikely that this compound acts to block
uptake via iron chelation. Benzoic acid derivatives have,reducing iron to render it more bioavailable for transport.
Since iron-deficiency anemia is an important problem however, been used extensively as chloride channel
blockers [50]. In this regard, it is of particular interestworldwide [31], the discovery of activators of iron trans-
port is certainly not without merit and warrants future that 54C20 (5-phenyl-2-pyrrole propionic acid or PPP)
is a -aminobutyric acid (GABA) analog since stimulationconsideration. However, our primary intent in this inves-
tigation was to discover inhibitors of NTBI uptake in of GABA receptors results in increased chloride conduc-
tance [50–52]. A role for chloride channels in yeast ironorder to establish pharmacological reagents to aid in
molecular analysis of the mechanistic elements involved transport and metabolism has been identified [53], and
our observations therefore prompt the idea that mam-in iron transport.
Ten small molecule inhibitors of NTBI uptake were malian iron transport may also be coupled to this func-
tion. Experiments are underway to test this possibilitydiscovered in this screen with diverse structural features
(Table 1). We can not find any reports exploring their and to further explore the mechanism of action for the
other more potent inhibitor of NTBI uptake, 54N20.possible influences on these chemicals on iron trans-
port, and only two of the ten inhibited Tf-mediated up- The idea that common mechanistic elements may ex-
ist between NTBI and Tf-mediated iron uptake is sup-take. Five (56N08, 56N16, 55B05, 57H10, and 56M19)
were cytotoxic at higher concentrations, suggesting that ported by the discovery of 57N19 and 55L06. Both inhibi-
tors act in a dose-dependent manner to block NTBI andthe usefulness of these compounds and derivatives for
cell-based studies may be limited. It is unlikely that their Tf-mediated iron uptake. However, the IC50 values for
inhibition of the latter process are about an order ofcytotoxicity is related to interference of iron uptake over
the time frame of our experiments since cellular iron magnitude greater (63 and 20 M, respectively) than
their IC50 for inhibition of NTBI uptake (5 M for eachdepletion by strong chelators like DFO requires many
hours, if not days, to promote cell death. Three com- compound). This difference could be a consequence of
low cellular permeability since they would both presum-pounds (54C20, 54N20, and 56I18) are more attractive
candidates for future follow-up studies. Although 56I18 ably need to access intracellular endosomal compart-
ments to exert direct functional effects on the transport(benzoic acid) has metal binding properties, its IC50 for
Iron Transport Inhibitors
413
sponse to their iron deficiency. Other chelators, like di-
ethylenetriaminepentaacetic acid (DTPA), do not have
the same metal selectivity as DFO for iron and therefore
can exert pleiotropic effects. A class of compounds that
has proven useful in studies of cellular iron metabolism
are pyridoxal isonicotinoyl hydrazone (PIH) and its ana-
logs [54, 55]. These compounds bind iron in a 2:1 com-
plex and can actually deliver the metal to cells such that
proliferation is supported. These chelators also do not
remove iron from Tf but have been shown to mobilize
iron from cells after uptake by the Tf-mediated pathway,
serving as a shuttle to move the metal out of cells. Thus,
although they complex iron, the metal is still available for
cellular metabolism. A relatively new chelater, ICL670A,
which also binds iron in a 2:1 complex, is currently in
clinical trials for therapeutic use in iron chelation, but
little is known yet about its effects at the cellular level
[56]. In contrast to these chelating reagents, the ten
inhibitors identified in the NCI diversity set screen are
unlikely to block uptake by complexing iron. Some may
Figure 5. 55L06 and 57N19 Inhibit Iron Uptake in a Reversible possibly exert indirect effects, as we speculate 54C20
Manner and 56I18 might act on counter-ion flux to disrupt iron
To determine the reversibility of inhibition of Tf-mediated iron uptake uptake. Others (e.g., 54N20) may selectively interact with
(top), HeLa cells were incubated at 37C with 20 M 55L06 or 100
molecules involved in membrane translocation of NTBI.
M 57N19 for 1 hr, followed either by a 2 hr recovery period (filled
Finally, 57N19 and 55L06 might interfere with elementsbars) or by continued 1 hr incubation in the presence of the drug
common between NTBI and Tf-mediated iron uptake(open bars). 55Fe-Tf (13 nM) was then added for a further 2 hr incuba-
tion to determine iron uptake. Uptake was quenched by chilling the pathways.
cells on ice and incubating with 40 M unlabeled Fe-Tf for 1 hr to We hope that future use of these chemical tools will
displace surface bound 55Fe-Tf; lysates were collected to measure yield important insights into characteristics of NTBI and/
cell-associated radioactivity and protein content. 55Fe uptake was
or Tf-mediated iron uptake that will ultimately lead tonormalized to protein content and expressed as % of control (DMSO
target identification. The development of the calcein flu-alone). To test the reversibility of NTBI uptake inhibition (bottom),
orescence quenching method to screen for inhibitorsHeLa cells were incubated at 37C with 0.25 M calcein for 1 hr.
After extensive washing, cells were incubated with 5 M 55L06 or of these pathways establishes the necessary basis for
57N19 with and without a recovery period as described above. further discovery of additional small molecule inhibitors
Reversibility of fluorescence quenching was determined as % con- of iron transport. Our future efforts in chemical genetics
trol (DMSO alone).
will not only focus on the mechanistic characterization
of the inhibitors identified in this screen, but will also
of iron released from internalized Tf. Alternatively, these center on additional screening of different chemical li-
compounds may be catabolized such that their efficacy braries for inhibitors of both NTBI and Tf-mediated iron
is lost once they penetrate cells. The process of Tf- uptake.
mediated iron uptake also involves additional steps that
are unique from NTBI transport. For example, 57N19 or
55L06 could block endocytosis, the release of iron from Significance
Tf, or recycling of Tf receptors to the cell surface. There-
fore, it is possible that differences in the IC50 values Chemical genetics is an emerging field that takes ad-
vantage of small molecule libraries to dissect complexreflect differences in the mechanism of action of the
compounds on Tf-mediated uptake. While further stud- biological processes. Past use of small molecule an-
tagonists typically entailed “reverse” chemical genet-ies are clearly necessary to determine what specific
effects 57N19 and 55L06 have on the Tf receptor path- ics to conditionally eliminate protein function, and on
that basis to identify the target of inhibition. Studiesway, the fact that certain features of NTBI and Tf-medi-
ated iron uptake are similar (e.g., requirement for ferrire- of carrier-mediated transport to learn how nutrients,
iron, and other factors enter or exit cells have reliedduction) supports the simpler model that these small
molecule inhibitors may act on mechanistic elements heavily on the use of such pharmacological reagents,
and among many well-established examples are thethat are common to both pathways.
Our identification of this set of small molecule inhibi- use of ouabain to study the Na-K ATPase, of cytocha-
lasin B to inhibit glucose transport, and of derivativestors greatly expands the repertoire of pharmacological
reagents to study iron transport. To date, molecules that of the diuretic amiloride to identify and purify Na chan-
nels. There is a need, however, to develop “forward”have been characterized to inhibit uptake function as
iron chelators, like DFO. DFO chelates NTBI in a 1:1 chemical genetics approaches to discover small mole-
cules that interact with key elements in a pathway ofcomplex to block uptake, but does not release iron from
Tf and therefore does not directly interfere with Tf-medi- interest. Forward chemical genetics must be based
on a phenotypic screen of small molecule librariesated transport. To the contrary, cells depleted of iron
by DFO upregulate the number of Tf receptors in re- such that one can identify effectors by observing a
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(Fd  Ff)/Fd ratios were normalized by setting the average (Fd change in cellular properties. One important area of
Ff)/Fd ratio (Fmin) of negative control cells with no DFO nor Fe-NTAnutrient transport studies lacking pharmacological re-
(column 1) as 0, and the average (Fd Ff)/Fd ratio (Fmax) of positiveagents for advanced study concerns iron uptake. In
control cells with DFO and Fe-NTA (column 2) as 1. The normalized
this report, we establish the basis for a cell-based ratio for each well was then calculated as: (Ff  Fmin)/(Fmax 
forward chemical genetics screen. Our approach is Fmin). All equipment and robotic instrumentation used for screening
was provided by facilities at ICCB and is described at http://iccb.unique in that it enables rapid identification of transport
med.harvard.edu.inhibitors with the concurrent detection of cytotoxicity
of the compounds screened. Using this fluorescence-
Tf-Mediated Iron Transport Assaysbased method, we have screened the National Cancer
HeLa cells were washed with serum-free media and incubated with
Institute Diversity Set library to discover ten novel small 13 nM 55Fe-Tf at 37C with or without inhibitors at the concentrations
molecule inhibitors of non-transferrin bound iron up- shown in Figure legends. As a control, cells were incubated with
take. Only two of these compounds blocked iron up- vehicle alone (0.5% DMSO). At the end of the uptake period, cells
were rapidly chilled on ice, washed twice with ice-cold phosphate-take via transferring-mediated transport, thus estab-
buffered saline containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS),lishing the first pharmacological tools that distinguish
then incubated with 40 M unlabeled Tf for 1 hr to displace surfacedifferent pathways of cellular iron absorption.
bound 55Fe-Tf. Cells were washed twice with PBS and lysed with
600 l solubilization buffer (0.1% Triton X-100, 0.1% NaOH). Cell-
associated radioactivity was determined by liquid scintillationExperimental Procedures
counting and cell protein was measured using the Bradford assay
to calculate pmol 55Fe/mg cell protein.Fluorescence-Based Assay for the Uptake of Iron by HeLa
Cells as Detected by Changes in the Labile Iron Pool
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